Free Trial
NASDAQ:OTLK

Oncobiologics Q3 2025 Earnings Report

Oncobiologics logo
$1.04 -0.02 (-1.89%)
Closing price 10/1/2025 04:00 PM Eastern
Extended Trading
$1.06 +0.02 (+1.54%)
As of 06:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncobiologics EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Oncobiologics Revenue Results

Actual Revenue
$1.51 million
Expected Revenue
$1.66 million
Beat/Miss
Missed by -$157.00 thousand
YoY Revenue Growth
N/A

Oncobiologics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
12:00AM ET

Oncobiologics Earnings Headlines

Outlook Therapeutics Provides Update on Type A Meeting with FDA
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
See More Oncobiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncobiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncobiologics and other key companies, straight to your email.

About Oncobiologics

Oncobiologics (NASDAQ:OTLK) is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary. This global footprint enables the company to conduct end-to-end process development and scale-up operations, optimizing both development timelines and production costs in major biopharmaceutical markets.

The company’s pipeline comprises multiple biosimilar candidates targeting established therapies in oncology and supportive care, with programs at various stages of preclinical and clinical development. Oncobiologics advances its portfolio through a disciplined clinical strategy and selective partnerships designed to streamline regulatory pathways. By focusing on broadening patient access to proven biologic medicines, the company seeks to address unmet needs in the United States, Europe and other global regions with its upcoming biosimilar products.

View Oncobiologics Profile

More Earnings Resources from MarketBeat